The 12-month consensus price target is at $104.68. Pacira posted its Q2 earning July 31, reporting revenue of $47.2 million
More articles on Pacira Pharmaceuticals:
Pacira’s EXPAREL sales at $44.9M for Q2
Pacira Joins NPSF Coalition
Study: EXPAREL Infiltration Effectively Controls Postsurgical Pain
